Pharmaceutical Executive, Nov 1, 2011

Features

The Rx Club's 25th Anniversary Show

By Jennifer Ringler , Ben Comer

Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?

Prix Galien USA 2011

By Jeff Schindler

A celebration of achievement

Does a German Launch Make Sense?

Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?

Back Page

Fostering a Legacy of Leadership

By Jeff Schindler

Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.

Column

The Drug Shortages Struggle

By Jill Wechsler

Clamor for critical therapies prompts probes of prices, production practices.

Spotlight on OTCs

With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.

Pharma's Visit to the Plastic Surgeon

By Bill Drummy

The bigger the company, the thicker the sclerosis, the more they need to suck out the fat

The Pharma Revolution Recalibrated

Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.

Europe Tackles 'Advertising in Disguise' Fears

By Julian Upton

The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?

Agency Assignments: Managing the Hidden Costs

By Al Topin

Saving the agency/client relationship begins first with the people involved and defining accountability on both sides